Kolltan Adds $5M to Series A

Xconomy Boston — 

Kolltan Pharmaceuticals, the New Haven, CT-based developer of cancer drugs, said today it has raised an additional $5 million as part of its Series A financing, bringing the total round to $40 million. Kolltan, a spinout from the Yale University lab of Joseph Schlessinger, announced its initial $35 million financing in January. Investors in the Series A financing include Purdue Pharma, HBM BioCapital, the Pritzker/Vlock family, and other private life sciences investors.